1. Introduction
Teduglutide, an analog of glucagon-like peptide 2, is approved for the treatment of patients with short bowel syndrome (SBS) dependent on parenteral support [1, 2] . Based on pharmacologic activity and preclinical findings of this trophic hormone, the potential for hyperplastic changes was taken into consideration by regulatory agencies at the time of indication approval [1, 2] . Consequently, the prescribing information and product monographs propose close colonoscopic surveillance. Namely, patients should have a colonoscopy with removal of polyps before the initiation of treatment with teduglutide and follow-up colonoscopies during treatment [1, 2] . However, there are limited data on the development or progression of polyps in patients receiving teduglutide. The present study is not powered to challenge current surveillance recommendations, but this brief communication does provide additional, albeit limited post hoc, data regarding the baseline prevalence and incidence of potentially malignant or pre-malignant lesions in patients taking teduglutide. The data are derived from the three completed adult studies in the STEPS clinical trial series [3e5] for all patients who underwent colonoscopy and had polyps at baseline or during subcutaneous administration of teduglutide 0.05 mg/ kg/day.
Material and methods
This post hoc analysis included all individual colonoscopy data from the double-blind, placebo-controlled STEPS (NCT00798967; EudraCT 2008-006193-15) study [3] and its two open-label extension studies; STEPS-2 (NCT00930644; EudraCT 2009-011679-65) [4] , and STEPS-3 (NCT01560403) [5] . The flow of patients across the STEPS clinical trial series has been published in Seidner et al. [5] Patients eligible to participate in STEPS had short bowel syndrome and intestinal failure (SBS-IF), were parenteral support dependent for !12 months, and required parenteral support !3 times weekly. Patients in STEPS-2 had to have completed 24 weeks of treatment (teduglutide or placebo) in STEPS [4] and patients in STEPS-3 had to have completed 24 months of teduglutide in STEPS-2 [5] . All patients in this post hoc analysis received teduglutide. All patients had provided written informed consent for study participation. All studies were conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation and Good Clinical Practice, and were approved by local institutional review boards/independent ethics committees/ research ethics boards.
The study protocol required a baseline colonoscopy for all patients with colon-in-continuity except those who had a normal colonoscopy within six months of their screening visit. The colonoscopy was performed at the end of the parenteral support stabilization period (baseline study visit) and before randomization to rule out malignant and high-grade dysplastic lesions. All benign gastrointestinal polyps had to be removed before randomization for patients to be eligible for enrollment. An end-of-study colonoscopy was required for all enrolled patients at final study visit in STEPS-2 (Month 24) and STEPS-3 (Month 36) or at the early termination visit for the extension studies. The study protocol did not preclude surveillance colonoscopies, if needed; collectively these post-baseline procedures are referred to as post-exposure colonoscopies. Information regarding polyps was collected via patient electronic case report forms; a histology report for any resected lesions was not required. Because the nature of this analysis was to report individual colonoscopy data, only descriptive statistics are provided.
Results
In the STEPS studies, 73 patients (mean [SD] age 49. 8 [14.14] years; women 57.5%) had a remnant colon and received a prerandomization baseline colonoscopy ( Supplementary Table 1 ). No post-exposure protocol colonoscopy was scheduled in the STEPS study. In the STEPS-2 and STEPS-3 populations, of the 65 patients who had a colon 50 patients (77%; mean age 51.5 [13.31] years; women 56.0%) had a protocol-mandated post-exposure colonoscopy. A summary of the colonoscopy visits and results for each individual STEPS study can be found in Supplementary Tables 1e3. Polyps were reported in nine of 73 patients who underwent the baseline colonoscopy ( Table 1 ). Five of the nine patients had one polyp each and the remaining four patients had two or more polyps. In these patients, the duration of parenteral support, an indirect measure of SBS-IF disease duration, ranged from one to !24 years. Table 2 provides the detailed data for the colon polyps reported in nine (mean age 49.6 [8.80] years; women 77.8%; 193.7 [52.24] per 100 patient-years) of 50 patients who underwent postexposure colonoscopy. In these nine patients, polyps were detected in three patients who had polyps removed at the baseline colonoscopy (n ¼ 2) or during the 24-month STEPS-2 colonoscopy (n ¼ 1). The polyps in these three patients were located in colon/ rectum (baseline) and transverse colon/ascending colon/cecum (post-exposure) in patient No. 6, in rectum (baseline) and colorectal (post-exposure) in patient No. 8, and colon (STEPS-2) and colon (post-exposure) in patient No. 10. The duration of teduglutide exposure at the time of polyp discovery in the nine patients ranged from eight to 36 months. Histological analyses in seven patients reported no evidence of malignancy or high-grade dysplasia; various adenomas were reported in 5 patients ( Table 2) .
A duodenal polyp (no histology available), detected at gastroscopy in a 64-year-old man, is not included in the analysis; this patient had a history of smoking/asbestos exposure and was being investigated for a non-small cell lung cancer (STEPS-2; the duration of teduglutide exposure at polyp detection was 3 months following completion in STEPS where placebo was received).
Discussion
In average risk adults (ie, no history of adenomatous polyps or colorectal cancer), the American Cancer Society recommends screening as early as 45 years of age [6] . An analysis of 9100 colonoscopies from a population-based US registry cohort (mean age, 60 years), comprising 68% screening and 32% surveillance colonoscopies reported adenoma rates of 25% and 37%, respectively [7] . In patients who had no polyp detected at a baseline screening colonoscopy but had a second surveillance colonoscopy within 5.5 years the rate of adenoma was 16e41% [8] .
In the STEPS clinical trial series, polyps were detected during the screening baseline colonoscopy in 12% (9/73) of patients with SBS-IF, aged 39e75 years. Among the patients who received long-term teduglutide and had post-exposure colonoscopies, polyps were detected in 18% (9/50) of patients. This 24-and 36-month colonoscopy data could be considered a short-term second protocoldriven, not risk-driven, 'surveillance' colonoscopy. Collectively in this post hoc analysis, the reported polyp detection rate for a SBS-IF population is at the low range of the rates reported in the literature for the general population [7, 8] . Variations in patient demographics and baseline characteristics may account for the observed differences in rates of polyp detection. No histological information is available for the nine patients who had polyps before receiving any study treatment. Of the seven histology analyses performed in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66   67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119  120  121  122  123  124  125  126  127  128  129  130 patients who received long-term teduglutide, there was no evidence of malignancy or high-grade dysplasia. This post hoc analysis has some limitations. Although this analysis used all available colonoscopy data collected, the STEPS study program was not designed to investigate polyp formation in detail. Particularly, the study design permitted a comparison between teduglutide and placebo for the first 24 weeks; thereafter, all patients received teduglutide for up to two years. Furthermore, the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66   67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119  120  121  122  123  124  125  126  127  128  129  130 protocol was not designed to capture baseline polyp characteristics, risk factors for the development of polyps or colorectal cancer, or prior colonoscopies in patients >50 years of age. The conclusions are, therefore, constrained by the small population size, the descriptive nature of the findings, and the limited data-reporting requirements for the colonoscopy and histology. It is possible that polyps identified during the follow-up colonoscopy did not develop de novo between procedures, but rather were undetected during the baseline colonoscopy. We did not include data from other clinical studies, noted in some regional prescribing information documents [1] , that used higher doses than the approved 0.05/mg/ day teduglutide (2 cases) or included intestinal polyps (2 cases).
Overall, these colonoscopy results support the recommendation in the teduglutide prescribing information regarding colonoscopic surveillance [1, 2] . A polyp detection rate of 12% supports baseline colonoscopy before starting teduglutide. Moreover, careful screening at the baseline is critical to detect cancers that would otherwise preclude teduglutide therapy and for the detection and removal of polyps that might be at risk of progression during treatment. This would also minimize the risk of undetected polyps, which, if detected at the recommended 1e2 year colonoscopy, would necessitate earlier or more frequent surveillance. Most patients (>70% with no polyps at baseline or follow up colonoscopy) could then be monitored every 5 years thereafter. An ongoing global, observational SBS registry (NCT01990040; EUPAS7973) is designed to provide more detailed information on the development of colon polyps in patients with SBS-IF and may lead to revision of the current regulatory guidance on surveillance colonoscopy. Newer mechanical endoscopic devices such as magnifying chromoendoscopy and magnifying narrow-band imaging have markedly improved detection of adenomas and polyps [9] . It is possible that these novel diagnostics along with histological, molecular, and stool-based techniques may be adopted, after appropriate validation, for screening and surveillance of patients treated with teduglutide.
Conclusion
These data provide some additional information about the risk of polyp formation in patients with SBS-IF and in patients treated with teduglutide. They support the recommendations for a baseline, pre-treatment colonoscopy and subsequent surveillance colonoscopies in the teduglutide regulatory prescribing labels which should be considered in conjunction with local guidelines and policies for colorectal cancer screening in average risk and high risk individuals.
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